Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.33 |
| ▸ | KDM1A | O60341 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.30 |
| ▸ | EZH2 | Q15910 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7125031 | 0.85 | NPC1 (0.37) | NPC1RAB9ACHRNA7SLC6A2SLC6A4 | |
| SCHEMBL7115153 | 0.85 | SLC6A3 (0.35) | EPHX2CHRNA7SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL7115178 | 0.85 | SLC6A4 (0.38) | KDM1ASLC6A2SLC6A4SLC6A3 | |
| SCHEMBL7123917 | 0.84 | HDAC4 (0.39) | CHRNA7SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL7124866 | 0.84 | SLC6A4 (0.35) | CHRNA7SLC6A2SLC6A4SLC6A3EZH2 | |
| SCHEMBL7113482 | 0.82 | EPHX2 (0.37) | EPHX2NPC1RAB9ACHRNA7KDM1A | |
| SCHEMBL7120638 | 0.82 | ALDH1A1 (0.34) | CHRNA7SLC6A2SLC6A4SLC6A3ALDH1A1 | |
| SCHEMBL7120695 | 0.82 | EPHX2 (0.38) | EPHX2NPC1RAB9ACHRNA7KDM1A | |
| SCHEMBL7125131 | 0.82 | EPHX2 (0.49) | EPHX2NPC1RAB9ACHRNA7SLC6A2 | |
| SCHEMBL7114304 | 0.81 | PTGDR2 (0.37) | EPHX2NPC1RAB9AKDM1APTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030069296-A1 | Substituted-aryl 7-aza[2.2.1]bicycloheptanes for the treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-04-10 | — | — | US | claimed |
| US-20030069296-A1 | Substituted-aryl 7-aza[2.2.1]bicycloheptanes for the treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030069296-A1 | Substituted-aryl 7-aza[2.2.1]bicycloheptanes for the treatment of disease | CYP7B1, UGT2B7, CYP1B1 | EPHX2 194/4885NPC1 267/4885RAB9A 491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.